文献速递神经肌肉病

创新肌萎缩侧索硬化临床试验:挑战既定秩序

Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order.
PubMed 文献 · Neurology · 2021-07-27

该研究针对肌萎缩侧索硬化(ALS)临床试验的设计难题,评估了患者选择和分析策略两大主题,并与欧洲药品管理局讨论。基于5项安慰剂对照试验(n=988)、4个人群队列(n=5,100)及PRO-ACT数据库中2,436例安慰剂分配患者的数据,提出设计修改可减少30.5%样本量和35.4%安慰剂暴露时间,并建议采用灵活设计框架。

要点

  • 提出的设计修改可减少30.5%样本量和35.4%安慰剂暴露时间
  • 利用预后生存模型可纳入更大比例人群并提高泛化性
  • 灵活设计框架可适应设计阶段不准确的假设,减少无效治疗暴露

核心结论

  • 提出的设计修改可减少30.5%样本量和35.4%安慰剂暴露时间,并可能成为未来ALS临床试验的蓝图。

研究设计与样本

  • 评估了ALS关键3期临床试验设计的两个主题:患者选择和分析策略,并与欧洲药品管理局讨论。
  • 使用5项安慰剂对照临床试验(n=988)、4个人群队列(n=5,100)和PRO-ACT数据库中2,436例安慰剂分配患者的数据。
  • 通过模拟确认每个 proposed 设计修改的有效性,并在假设情景中展示。

主要发现

  • 与经典试验设计相比,提出的设计修改减少样本量30.5%和安慰剂暴露时间35.4%。
  • 利用预后生存模型可潜在纳入更大比例人群并最大化泛化性。
  • 灵活设计框架可在设计阶段假设不准确时自然调整试验持续时间。
  • 在无效情况下,缩短随访时间并最小化患者对无效治疗或安慰剂的暴露。

临床怎么用

  • 优化资源利用、拓宽 eligibility 标准并最小化无效治疗和安慰剂暴露对ALS等疾病至关重要。
  • 提出的设计修改可规避重要陷阱,并可能作为该人群未来临床试验的蓝图。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Development of effective treatments for amyotrophic lateral sclerosis (ALS) has been hampered by disease heterogeneity, a limited understanding of underlying pathophysiology, and methodologic design challenges. We have evaluated 2 major themes in the design of pivotal, phase 3 clinical trials for ALS-(1) patient selection and (2) analytical strategy-and discussed potential solutions with the European Medicines Agency. Several design considerations were assessed using data from 5 placebo-controlled clinical trials (n = 988), 4 population-based cohorts (n = 5,100), and 2,436 placebo-allocated patients from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. The validity of each proposed design modification was confirmed by means of simulation and illustrated for a hypothetical setting. Compared to classical trial design, the proposed design modifications reduce the sample size by 30.5% and placebo exposure time by 35.4%. By making use of prognostic survival models, one creates a potential to include a larger proportion of the population and maximize generalizability. We propose a flexible design framework that naturally adapts the trial duration when inaccurate assumptions are made at the design stage, such as enrollment or survival rate. In case of futility, the follow-up time is shortened and patient exposure to ineffective treatments or placebo is minimized. For diseases such as ALS, optimizing the use of resources, widening eligibility criteria, and minimizing exposure to futile treatments and placebo is critical to the development of effective treatments. Our proposed design modifications could circumvent important pitfalls and may serve as a blueprint for future clinical trials in this population.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. van Eijk RPA, Nikolakopoulos S, Roes KCB, et al. Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order. Neurology. 2021. PMID: 34315786. doi:10.1212/WNL.0000000000012545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。